More than half of U.S. adults might be candidates for Ozempic
More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug semaglutide, a new analysis finds. Sold as Ozempic for treating diabetes … Click to Continue »
View original article
Contributor:
